Isotretinoin Exposure and Risk of Inflammatory Bowel Disease
Open Access
- 1 December 2014
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 150 (12) , 1322-1326
Abstract
Isotretinoin (13-cis-retinoic acid) is a synthetic vitamin A derivate that is standard treatment for recalcitrant severe nodulocystic acne. Isotretinoin binds to and activates nuclear retinoic acid receptors, thereby regulating cell proliferation and differentiation. A possible association between isotretinoin exposure and inflammatory bowel disease (IBD) has been a subject of debate in the literature.Keywords
This publication has 20 references indexed in Scilit:
- Isotretinoin Use and the Risk of Inflammatory Bowel Disease: A Population-Based Cohort StudyJournal of Investigative Dermatology, 2013
- Isotretinoin Use and the Risk of Inflammatory Bowel Disease: A Case–Control StudyAmerican Journal of Gastroenterology, 2010
- Isotretinoin Is Not Associated With Inflammatory Bowel Disease: A Population-Based Case–Control StudyAmerican Journal of Gastroenterology, 2009
- Isotretinoin-associated Pan-enteritisJournal of Clinical Gastroenterology, 2008
- The Prevalence and Geographic Distribution of Crohn’s Disease and Ulcerative Colitis in the United StatesClinical Gastroenterology and Hepatology, 2007
- Isotretinoin and Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2007
- Possible Association Between Isotretinoin and Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2006
- Use of isotretinoin (Accutane) in the United States: Rapid increase from 1992 through 2000Journal of the American Academy of Dermatology, 2002
- The differential diagnosis and comorbidity of hidradenitis suppurativa and perianal Crohn's diseaseInternational Journal of Colorectal Disease, 1993
- Isotretinoin-associated proctosigmoiditisGastroenterology, 1987